^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The Panel recommends gemcitabine monotherapy as one option for front-line therapy for patients with metastatic disease (category 1) or locally advanced disease and a good performance status.
